P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough

Gefapixant/AF-219, a selective inhibitor of the P2X3 receptor, is the first new drug other than dextromethorphan to be approved for the treatment of refractory chronic cough (RCC) in nearly 60 years. To date, seven P2X subtypes (P2X1-7) activated by extracellular ATP have been cloned, and subtype se...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Wen-Wen, Wang, Si-Yu, Zhang, Yu-Qing, Wang, Yao, Fan, Ying-Zhe, Guo, Chang-Run, Li, Xing-Hua, Lei, Yun-Tao, Wang, Wen-Hui, Yang, Xiao-Na, Hattori, Motoyuki, Li, Chang-Zhu, Wang, Jin, Yu, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014320/
https://www.ncbi.nlm.nih.gov/pubmed/35465163
http://dx.doi.org/10.1016/j.csbj.2022.03.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014320/
https://www.ncbi.nlm.nih.gov/pubmed/35465163
http://dx.doi.org/10.1016/j.csbj.2022.03.030

Ejemplares similares